AbCellera Biologics (ABCL) Expected to Release Quarterly Earnings on Wednesday

AbCellera Biologics (NASDAQ:ABCL) is anticipated to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.1443) per share and revenue of $7.8480 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.08. The company had revenue of $8.31 million during the quarter, compared to analysts’ expectations of $5.41 million. AbCellera Biologics had a negative net margin of 181.75% and a negative return on equity of 14.86%. During the same period in the previous year, the company earned ($0.15) EPS. On average, analysts expect AbCellera Biologics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

AbCellera Biologics Stock Performance

Shares of ABCL opened at $5.71 on Monday. The firm has a market capitalization of $1.74 billion, a P/E ratio of -11.90 and a beta of 1.14. The stock’s fifty day simple moving average is $6.15 and its 200 day simple moving average is $4.62. AbCellera Biologics has a twelve month low of $2.74 and a twelve month high of $8.44.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on ABCL shares. Wall Street Zen lowered AbCellera Biologics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Cantor Fitzgerald assumed coverage on AbCellera Biologics in a report on Tuesday, May 5th. They set an “overweight” rating and a $7.00 target price for the company. Benchmark raised shares of AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (d-)” rating on shares of AbCellera Biologics in a report on Friday, July 17th. Finally, JonesTrading started coverage on shares of AbCellera Biologics in a research report on Friday, April 10th. They set a “buy” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Engineers Gate Manager LP purchased a new position in shares of AbCellera Biologics in the fourth quarter valued at $38,000. Magnetar Financial LLC acquired a new position in AbCellera Biologics in the 4th quarter worth $49,000. Lantern Wealth Advisors LLC purchased a new position in AbCellera Biologics in the 2nd quarter valued at about $51,000. Oxford Asset Management LLP acquired a new stake in shares of AbCellera Biologics during the fourth quarter valued at about $51,000. Finally, Invesco Ltd. increased its position in shares of AbCellera Biologics by 114.6% during the first quarter. Invesco Ltd. now owns 24,146 shares of the company’s stock worth $54,000 after acquiring an additional 12,893 shares during the last quarter. 61.42% of the stock is owned by institutional investors and hedge funds.

About AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.